Xylyx Bio


Xylyx Bio is dedicated to transforming regenerative medicine through bioengineering, with a focus on bioengineered human organs and extracellular matrix technologies. Their mission is to save lives by significantly increasing the availability of human organs for transplantation, utilizing innovative platforms like xenogeneic cross-circulation to develop fully functional, anatomically compatible organ grafts. They are committed to pioneering solutions for organ shortages, advancing tissue regeneration, and improving clinical outcomes through their cutting-edge research, products, and collaborations.

Industries

biotechnology
health-care
life-science

Nr. of Employees

small (1-50)

Xylyx Bio

Brooklyn, New York, United States, North America


Products

Tissue-specific dECM coating and hydrogel kits

Ready-to-use, quality-controlled decellularized ECM kits processed into coatings and hydrogels for tissue-specific in vitro culture and disease modeling.

Assay kits for disease modeling (IPF, NASH, metastasis)

Assays and kits designed to model specific disease states (e.g., human IPF, NASH) and metastatic microenvironments using tissue-specific ECM substrates.

Bioactive ECM-derived peptide formulations

Combinations of ECM-derived matrikine peptides developed to activate regenerative pathways and modulate inflammation for tissue repair; evaluated in topical applications and clinical studies.


Services

Ex vivo organ rehabilitation service

Ex vivo rehabilitation of donor organs using xenogeneic cross-circulation and normothermic physiologic support to restore organ function prior to transplantation.

R&D partnerships and translational collaborations

Collaborative research and licensing partnerships with academic laboratories and clinical investigators to advance organ rehabilitation methods and translational studies.

Expertise Areas

  • Organ bioengineering and ex vivo organ rehabilitation
  • Decellularized extracellular matrix biomaterials
  • Disease-relevant in vitro models and assay development
  • Peptide-based regenerative therapeutics
  • Show More (4)

Key Technologies

  • Xenogeneic cross-circulation (porcine bioreactor) for ex vivo support
  • Normothermic extracorporeal organ perfusion
  • Tissue-specific decellularized ECM hydrogels and coatings
  • Matrikine peptide combinations (bioactive ECM-derived peptides)
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.